Precision BioSciences (DTIL) Completes License Deal with TG Therapeutics (TGTX) for Cell Therapy Azer-Cel streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
TG Therapeutics, Inc. (NASDAQ: TGTX) shares are trading lower Tuesday, though the stock remains up 18% over the past five days. Here's a look at what's going on.
Wednesday, Precision BioSciences Inc (NASDAQ: DTIL) announced the completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel), Precision's lead allogeneic CAR T candidate for cancer.
- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales- Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients who Relapse Follow.